Press Releases

Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec

First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline

- Late-breaking oral abstract presented at the World Congress of Gastroenterology -

- Understand AD: A Day in the Life, Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and Understanding of this Unrelenting, Chronic Disease -

- Praluent continues to be available to patients in the U.S. -

- First targeted biologic in the European Union to receive marketing authorization for use in atopic dermatitis -

- In preclinical studies, trispecific antibodies show exceptional potency against diverse HIV viruses -

- Investigational RNAi Therapeutic Patisiran Meets Primary and All Secondary Endpoints, with Highly Significant Reduction In Neuropathy Progression and Improvement in Quality of Life at 18 Months Relative to Placebo -

- Late-breaking oral abstract of Phase 3 CAFÉ study presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress -

-- More adults reached HbA(1c) target at 8 and 12 weeks versus those receiving insulin glargine 100 Units/mL --

- Investigational dupilumab reduced severe asthma attacks and improved lung function -

- An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio -

- Health care providers anticipating initial shipments by early August to kick off influenza immunization season -

- Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio -

- Data presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) -

- New DELIVER 3 Real-World Toujeo® Observational Study Confirms Reduction of Hypoglycemia in Real-Life Setting -

- All subgroups treated with Soliqua 100/33 achieved a mean HbA1c of below 7 percent after 30 weeks -

- Oral presentation provides first REGN2810 data in patients with advanced cutaneous squamous cell carcinoma (CSCC) -

- Kevzara is now available to U.S. patients -

-- New Initiative Encourages Americans to Help Reduce Air Pollution & Enjoy the Outdoors this Spring Allergy Season --

Op-Ed by Olivier Brandicourt

- New U.S. survey reveals significant unmet needs when it comes to treatments and support for those living with RA -

- New action date for Kevzara U.S. BLA is May 22, 2017 -

- Monthly dosing schedule now approved in both United States and European Union -

- New U.S. indication approved for Thymoglobulin [anti-thymocyte globulin (rabbit)]; first since 1998 -

- New toothpaste introduced by the trusted leader in mouthwashes for more than 30 years helps motivate kids to brush their teeth -

- DELIVER 2 Data Showed Reduction in Hypoglycemic Events Related to Inpatient or Emergency Department Visits -

- Dupixent will be available later this week to U.S. patients suffering from this chronic and debilitating form of eczema -

- During Multiple Myeloma Month Sanofi Genzyme is Reinforcing its Commitment to Help Patients Live with the Second Most Common Blood Cancer in the World -

The makers of Xyzal® Allergy 24HR, now available over-the-counter (OTC) at full prescription strength, are teaming up with Dr. Neeta Ogden to Encourage Allergy Sufferers to 'Wise Up, Rise Up'

Respiratory Syncytial Virus is the most common cause of lung inflammation and pneumonia in infants

- Late-breaking oral abstract to be presented today at the Annual Meeting of the American Academy of Dermatology -

- Praluent continues to be available to patients in the U.S. -

- Antihistamine Offers 24-Hour Relief to Adults and Children with Seasonal and Year-Round Allergies -

Employee holiday drive echoes company’s holistic approach in supporting Monroe County Head Start and Pocono Alliance families

Data also Shows Men Consider Sexual Health to be an Important Priority

- In the MONARCH Study, Sarilumab Monotherapy Demonstrated Superiority Over Adalimumab Monotherapy in Adults with Active Rheumatoid Arthritis -

2016 could be the year of the last case of wild poliomyelitis worldwide

- U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety -

- Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress -

Funds will be used for phase II development and manufacturing

- Joshua Riff, M.D., Named Chief Executive Officer -

- Adlyxin™ is approved as Lyxumia® in more than 60 countries -

- World's largest influenza vaccine manufacturer expects to distribute more than 65 million vaccine doses to help protect people six months and older against the flu -

-- Findings reveal that some patients are frustrated and discontinued medication because they were not reaching their individualized A1C target quick enough --

Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis.

- Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide -

- These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 -

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -

- Collaborations Will Work towards Predicting Medication Adherence -

- Dupilumab is first systemic therapy to show positive Phase 3 results in patients with moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease marked by widespread rash, itching and associated psychosocial comorbidities -

Pre-clinical immunogenicity and efficacy data published in Journal of Virology

Praluent is now covered by most health insurance and Medicare plans

- FDA decision anticipated in August 2016 -

America's Leading National Consumer Research Survey Ranks ACT Advanced Care #1 in "Oral Care" Category

Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids

Six researchers each receive $1.625 million in "Pathway to Stop Diabetes®" awards

- Aims to advance animal health though internet-connected technology and networks -